Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients
In this single-center study, patients tolerated higher doses of antimetabolite immunosuppression, and the incidence and frequency of myelosuppressive events were reduced while on LTV compared to VGC. This evidence expands upon the current literature demonstrating improved tolerability of LTV in LTX recipients.
Authors
- Ambalavanan Arunachalam (ORCID: https://orcid.org/0000-0002-0363-7889)
- Jacob Wang
- Alan Betensley (ORCID: https://orcid.org/0000-0002-5538-6831)
- M. Venkata Subramani (ORCID: https://orcid.org/0000-0003-3545-2747)
- Alyson Prom (ORCID: https://orcid.org/0000-0002-0727-2135)
- Catherine N. Myers (ORCID: https://orcid.org/0000-0002-3761-153X)
- Nicole Borkowski (ORCID: https://orcid.org/0000-0001-8650-6456)
- Hanna L. Kleiboeker (ORCID: https://orcid.org/0000-0003-3149-6558)
- Rade Tomic (ORCID: https://orcid.org/0000-0003-2394-1287)
- Krista Paplaczyk (ORCID: https://orcid.org/0000-0002-3115-1210)
- Jennifer Wright
- Brad Miner
Institutions
- Northwestern University (US)
- Northwestern Memorial Hospital (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1111/ctr.70033
- Citations
- 3
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.16